ARTICLE | Product Development
CAR Ts make the move to earlier lines of treatment despite access barriers
Kite reports first-line Yescarta data as companies across the field set their sights on treating patients earlier
December 11, 2020 8:48 PM UTC
CAR T manufacturers and payers are still negotiating access for B cell lymphoma patients without other treatment options, but that hasn’t stopped companies from pressing on into earlier lines of treatment.
With evidence of durability mounting and strategies to mitigate toxicity bringing down the safety risks, CAR T developers are mapping out strategies to reach more patients. One area where they’ve begun to break ground is moving the new modality earlier in the course of treatment. ...